Mohamed Nasser
Epilepsy · Weston, FLNPI 1699279638
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,950 of the $28,388 with a category attached, or 98.5%. Viiv Healthcare Company accounts for 98.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $18,329 and has fallen 99.9% since, to $15 in 2025.
Across 22 payments — averaging $1290.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$28K
- Neurelis, Inc.$108
- Jazz Pharmaceuticals Inc.$91
- Neuropace, Inc.$62
- UCB, Inc.$37
- GSK$19
- plus $15 from 1 others
What the payments were for
- Speaking & faculty fees$27,95098%
- Travel & lodging$850%
- Food & beverage$3531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 8 | $28,057 |
| Neurelis, Inc. | 3 | $108 |
| Jazz Pharmaceuticals Inc. | 3 | $91 |
| Neuropace, Inc. | 3 | $62 |
| UCB, Inc. | 2 | $37 |
| GSK | 1 | $19 |
| Aucta Pharmaceuticals, Inc. | 2 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- APRETUDE$27,950
How this compares
$28,388 in reported general payments places this provider in the 75th percentile of 23 epilepsy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 13 | $48,340 |
| Lacosamide | 56 | $13,538 |
| Levetiracetam | 161 | $5,366 |
| Clobazam | 40 | $4,035 |
| Valproic AcidValproic Acid (As Sodium Salt) | 15 | $839 |
| Oxcarbazepine | 12 | $777 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $761 |
| Gabapentin | 27 | $623 |
| Lamotrigine | 29 | $579 |
| Topiramate | 40 | $505 |
| Divalproex Sodium | 11 | $360 |
| Primidone | 12 | $334 |
| Mirtazapine | 12 | $128 |
| Donepezil Hcl | 17 | $118 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Weston
- Huan HuynhWeston$3K
- Brian CostellBoca Raton$469K
- Andrew LermanMiami$249K
- Alberto Pinzon ArdilaMiami$144K
- Jaivir RathoreOrlando$38K
- Dipali NemadeOrlando$38K
- William TatumJacksonville$28K
- Brin FreundJacksonville$18K
- Miguel Melo-BicchiMiami$15K
- Claudio OsorioTampa$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.